Apollomics vs Immuron
APLM and IMRN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How APLM and IMRN compare
Immuron scores higher on the StockData Score (4 against 0 for Apollomics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | APLM | IMRN |
|---|---|---|
| Size and price | ||
| Share price | $17.68 | $0.875 |
| Change, 1 year | 7.0% | −45.6% |
| Change, 5 years | – | −74.6% |
| Beta (5Y) | 0.68 | 0.37 |
| Employees | 14 | 7 |
| StockData Score | ||
| Total score | 0 | 4 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 2 (better) |
| Health score | 0 | 1 (better) |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | – | 5.9% |
| Revenue growth, 5Y average | – | 121% |
| Profitability | ||
| Gross margin | – | 64.5% |
| Operating margin | – | −49.9% |
| Net margin | – | −47.7% |
| FCF margin | – | −42.3% |
| Financial health | ||
| Interest coverage | – | −261.7× |
| Current ratio | 0.96 | 7.26 (better) |
| Piotroski F-score | – | 5 |
| Ownership | ||
| Held by institutions | – | 0.02% |
| Held by insiders | 76.0% | 1.9% |
| Insider net buying, 12 months | $8.3M | – |
Go deeper
- APLM stock overview
- APLM income statement
- APLM valuation and score
- IMRN stock overview
- IMRN income statement
- IMRN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.